The severity of the dysplasia reduced from high grade to low grade in the patients, the 5th International AIDS Malignancy Conference in Bethesda, Maryland, USA, was told.
HspE7 is designed to treat anal dysplasia caused by human papillomavirus and prevent its progression to anal cancer.
Researcher Professor Joel Palefsky reported on the 6-month evaluation of the first 22 patients to receive the treatment.
The positive results were seen in 16 of the 22 patients.
|HspE7 reduced dysplasia from high to low grade in 75% of patients.|
|Fifth International Aids Malignancy Conference|
HspE7, developed by Stressgen, is a recombinant fusion product composed of heat shock protein 65 from Mycobacterium bovis BCG and the protein E7.
Professor Palefsky, of the University of California, San Francisco, USA, said, "At the 5th International AIDS Malignancy Conference, it has become increasingly apparent that anal dysplasia is an important public health problem, especially among HIV-infected gay men.
"Anal dysplasia is more common than anyone had previously known, and it can have serious medical implications if left untreated. New approaches to the treatment of anal dysplasia are badly needed."
Report Copyright: Englemed Health News at http://www.internationalmedicalnews.com